Jeito Invests in Callio Therapeutics’ $187M Series A to Advance Next-Gen Cancer Therapies

By Daniella Parra Jeito Capital said it invested in Callio Therapeutics’ $187M Series A round to support its next-generation multi-payload antibody-drug conjugates (ADCs) for cancer treatment. Callio Therapeutics is a biotechnology company developing multi-payload ADCs that says it aims to...